QP Wealth Management LLC Acquires 5,851 Shares of Revolution Medicines, Inc. $RVMD

Posted by George Bondi on Oct 21st, 2026

QP Wealth Management LLC purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,851 shares of the company’s stock, valued at approximately $1,201,000. Revolution Medicines comprises approximately 1.8% of QP Wealth Management LLC’s investment portfolio, making the stock its 21st largest holding.

Several other hedge funds also recently made changes to their positions in the company. Alphabet Inc. bought a new stake in shares of Revolution Medicines in the 2nd quarter worth approximately $551,843,000. Assenagon Asset Management S.A. grew its stake in Revolution Medicines by 987.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock worth $447,710,000 after buying an additional 1,980,699 shares during the last quarter. ABS Investment Management LLC bought a new position in Revolution Medicines during the 2nd quarter worth $337,104,000. Bank of America Corp DE bought a new position in Revolution Medicines during the 2nd quarter worth $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Revolution Medicines by 82.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock worth $170,862,000 after buying an additional 411,740 shares during the period. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Activity at Revolution Medicines

In related news, insider Mark Goldsmith sold 13,988 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the transaction, the insider owned 253,342 shares of the company’s stock, valued at approximately $50,475,860.08. This trade represents a 5.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret Horn sold 4,967 shares of Revolution Medicines stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $989,625.08. Following the completion of the sale, the chief operating officer directly owned 149,680 shares of the company’s stock, valued at approximately $29,822,243.20. The trade was a 3.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 290,991 shares of company stock worth $59,422,765. 7.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently commented on RVMD. Guggenheim upped their price target on shares of Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. TD Cowen reaffirmed a “buy” rating on shares of Revolution Medicines in a report on Thursday, October 8th. Wolfe Research reiterated an “outperform” rating and issued a $220.00 price objective on shares of Revolution Medicines in a research report on Monday, August 10th. Stifel Nicolaus lifted their price objective on shares of Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Finally, Morgan Stanley initiated coverage on shares of Revolution Medicines in a research note on Thursday, September 10th. They set an “overweight” rating and a $255.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $242.60.

Read Our Latest Stock Report on RVMD

Revolution Medicines Trading Up 7.9%

Shares of Revolution Medicines stock opened at $196.55 on Wednesday. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The firm has a market cap of $42.13 billion, a price-to-earnings ratio of -22.28 and a beta of 1.40. The business has a fifty day simple moving average of $202.54 and a 200-day simple moving average of $175.28. Revolution Medicines, Inc. has a fifty-two week low of $52.48 and a fifty-two week high of $224.31.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the company earned ($1.31) earnings per share. On average, equities analysts forecast that Revolution Medicines, Inc. will post -8.93 EPS for the current fiscal year.

About Revolution Medicines

(Free Report)

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.